SCHEMBL4559353

SCHEMBL4559353

O=C1Nc2cc(Cl)ccc2C1=C(Nc1ccc(CCN2CCCCC2)cc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR2A P28223 3/20 0.41
SIGMAR1 Q99720 3/20 0.41
DRD2 P14416 3/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
SMYD2 Q9NRG4 2/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
CHRM1 P11229 1/20 0.39
MCHR1 Q99705 1/20 0.39
LMNA P02545 1/20 0.38
HTR1A P08908 1/20 0.38
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
PAK1 Q13153 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559350 1.00 MEN1 (0.42) MEN1KMT2AHTR2ASIGMAR1DRD2
SCHEMBL4490014 0.92 GAA (0.47) MEN1KMT2AHTR2AGAAHTT
SCHEMBL4490221 0.92 GAA (0.47) MEN1KMT2AHTR2AGAAHTT
SCHEMBL4490016 0.92 GAA (0.47) MEN1KMT2AHTR2AGAAHTT
SCHEMBL4490218 0.92 GAA (0.47) MEN1KMT2AHTR2AGAAHTT
SCHEMBL4491690 0.91 GAA (0.45) HTR2AGAAHTTRAB9ACHRM1
SCHEMBL4491694 0.91 GAA (0.45) HTR2AGAAHTTRAB9ACHRM1
SCHEMBL480397 0.86 GLA (0.44) MEN1KMT2ASIGMAR1DRD2LMNA
SCHEMBL480395 0.86 GLA (0.44) MEN1KMT2ASIGMAR1DRD2LMNA
SCHEMBL4493434 0.85 MCHR1 (0.49) MEN1KMT2AHTR2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR MEN1 1288/4885KMT2A 3530/4885HTR2A 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.